Fig. 3 | Scientific Reports

Fig. 3

From: Efficacy and safety of Latilactobacillus sakei LB-P12 in patients with knee osteoarthritis: an exploratory randomized, double-blind, placebo-controlled clinical trial

Fig. 3Fig. 3

Improvements in secondary efficacy endpoints related to LB-P12 in the PP group. This figure illustrates the changes in key efficacy endpoints in the PP group, including after 12 weeks of intervention with LB-P12 compared to the control group. [(A) VAS (pain score), (B) IL-1β (inflammatory marker), (C) EQ-5D-5L (Quality of life), (D) C-reactive protein (CRP), (E) Erythrocyte Sedimentation Rate (ESR), (F) IL-6, (G) TNF-α, (H) Cartilage Oligomeric Matrix Protein (COMP), (I) Joint space width].

Back to article page